EnzyPep’s management team consists of Peter van Tilburg (CEO), Peter Quaedflieg (CSO) and Timo Nuijens (Lead Scientist). Together with the Scientific Advisory Board, this team incorporates a strong mix of entrepreneurial power, industrial peptide manufacturing expertise and scientific and operational proficiency. Supported by a skilled staff EnzyPep has the necessary human resources to achieve its business objectives.
Timo Nuijens graduated in Drug Innovation at the University of Utrecht. He performed his Ph.D. project on enzymatic peptide synthesis within DSM Innovative Synthesis B.V. (Geleen) under the supervision of Dr. Peter Quaedflieg (DSM Innovative Synthesis B.V.) and Prof. Rob Liskamp (Univ. Utrecht). His Ph.D. was obtained in May 2012. Since mid 2012 he is working as a lead scientist at Enzypep and has the responsibility of the scientific development and co-ordinating the R&D team in Geleen.
Peter Quaedflieg graduated from Eindhoven University in Chemical Engineering in 1988 and obtained a Ph.D. degree in Organic Chemistry with Prof. Jacques van Boom at Leiden University (The Netherlands) in 1993. In that year he joint DSM where he held various positions in R&D and process development. Currently he is Principal Scientist Route Scouting and Science Team Leader Organic Chemistry at DSM Innovative Synthesis in Geleen (The Netherlands). His research interests cover the synthesis of chiral pharmaceutical intermediates and peptides and the use of enzymes in organic and polymer synthesis.
Peter van Tilburg
Peter van Tilburg studied organic chemistry and worked for 12 years at DSM in different positions from process R&D, project management and new business development. In 1999 co-founded ChemShop and build the company from scratch to a very successful Process R&D and scale up company in the position of CEO. In 2007 successfully initiated an exit scenario by selling the company to Cambridge Major Laboratories US. Since 2007 continued as CEO of CML-Europe BV and build the company to one of the best FDA approved Process R&D and scale up companies for API’s in the world with app. 80 people at the site in the Netherlands. His knowledge of appropriate level of cGMP is profound. As of 2010 he is acting as a private investor and holds investments in several companies. In 2012 he founded Enzypep BV and retired from CML Europe April 2014.